8-KLeadership ChangesExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Nov 15, 2010)

Filed November 15, 2010For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced a significant addition to its Board of Directors with the appointment of Ms. Christine A. Poon, effective November 12, 2010. Ms. Poon brings extensive experience in the pharmaceutical sector, having previously served as Vice Chairman of the Board and Worldwide Chairman of the Johnson & Johnson Pharmaceuticals Group. Her expertise is expected to be valuable as she joins the Board's Compensation Committee and Corporate Governance Committee. This appointment is accompanied by a standard director compensation package, including annual cash retainers and meeting fees, as well as an initial stock option grant of 25,000 shares and future annual grants. The inclusion of a seasoned executive like Ms. Poon signals a continued focus on strategic governance and oversight, which is crucial for a company in the competitive biotechnology and pharmaceutical landscape.

Key Highlights

  • 1Regeneron Pharmaceuticals appointed Ms. Christine A. Poon as a new director, effective November 12, 2010.
  • 2Ms. Poon has a strong background in the pharmaceutical industry, previously holding key leadership roles at Johnson & Johnson.
  • 3She will serve on the Board’s Compensation Committee and Corporate Governance Committee, indicating a focus on executive compensation and company governance.
  • 4Ms. Poon received an initial stock option grant for 25,000 shares with an exercise price of $25.45.
  • 5Future annual stock option grants of 15,000 shares are planned, subject to continued service.
  • 6All stock option grants vest over three years and have a ten-year expiration period.
  • 7The appointment is detailed in an exhibit filed as a press release dated November 15, 2010.

Frequently Asked Questions

Ms. Christine A. Poon is a newly appointed director at Regeneron Pharmaceuticals. She has a distinguished career in the pharmaceutical industry, having served as Vice Chairman of the Board and Worldwide Chairman of the Johnson & Johnson Pharmaceuticals Group. She is also currently the dean of Ohio State University’s Fisher College of Business.

Ms. Poon will serve as a director on Regeneron's Board and will be a member of the Compensation Committee and the Corporate Governance Committee. This suggests a focus on executive compensation strategies and the company's overall governance structure.

Ms. Poon will receive an annual cash retainer and committee fees. She was granted 25,000 stock options upon appointment, with an exercise price of $25.45. She is also eligible for future annual stock option grants of 15,000 shares. All stock options vest over three years and expire ten years from the grant date.

The appointment of Ms. Poon, a seasoned executive with extensive experience in the pharmaceutical sector, is significant for Regeneron. It strengthens the Board's expertise in areas critical to the company's growth and strategic direction, particularly in governance and executive compensation, and indicates a commitment to robust oversight.